MZMin Zheng

Min Zheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Min Zheng has a total of 204 co-authors. Here are the top co-authors by number of shared publications:

  • Yun Zhou

    Department of Gynecology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou P.R. China

    13 shared publications
  • Lan Zhang

    Department of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital Yunnan Cancer Center Kunming China

    10 shared publications
  • Xiaojing Zheng

    Department of Gynecology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510060, China

    10 shared publications
  • Baoyue Pan

    Department of Gynecology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng Road East, Guangzhou, Guangdong, 510060, P. R. China

    9 shared publications
  • Yinan Jiang

    Department of Gynecology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China

    8 shared publications
  • Huiling Xiang

    Department of Gynecology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou P.R. China

    7 shared publications

Latest Publications

  • Open Access

    Correction: ZNF655 promotes tumor growth and chemoresistance by targeting MAFF-CCND1 axis in ovarian cancer

    by Ying Xiong, Jiaxin Yin, Yulin Huang, Nanbin Luo, Jiali Xia, Chongjie Tong, Min Zheng, Yinglan Liu

  • Open Access

    ZNF655 promotes tumor growth and chemoresistance by targeting MAFF-CCND1 axis in ovarian cancer

    by Ying Xiong, Jiaxin Yin, Yulin Huang, Nanbin Luo, Jiali Xia, Chongjie Tong, Min Zheng, Yinglan Liu

    Ovarian cancer (OC) has the highest mortality rate among gynecological malignancies. The role of zinc finger protein 655 (ZNF655) in cancer progression has been highlighted but remains unclear and needs further exploration. In this study, our findings revealed that ZNF655 is aberrantly upregulated in OC. Depletion of ZNF655 inhibited the malignant behaviors of OC, manifested by attenuated proliferation, promoted apoptosis, inhibited migration and reduced stem cell properties. Mechanistically, ZNF655 facilitated nuclear translocation of MAFF transcription factor in OC cells, leading to MAFF’s direct binding to the promoter of CCND1 and subsequent transcriptional activation of CCND1. Subsequent rescue experiments demonstrated that CCND1 plays a critical role in mediating ZFN655-dependent proliferation and stemness maintenance. Notably, ZNF655 overexpression conferred paclitaxel resistance in OC cells, suggesting clinical implications for chemoresistance. These in vitro findings were corroborated by murine xenograft models, where ZNF655-overexpressing tumors exhibited accelerated growth kinetics and elevated Ki-67 indices. Importantly, clinical correlation analysis of OC specimens revealed that ZNF655 overexpression correlated with poor patient outcome in OC. In conclusion, these results not only advance the understanding of the molecular mechanisms underlying OC progression but also identify ZNF655 as a potential preclinical therapeutic target for OC treatment.


  • Open Access

    The efficacy and peripheral blood predictors in recurrent platinum-resistant ovarian cancer patients treated with immune checkpoint inhibitors

    by Baoyue Pan, Xiaojing Zheng, Yongwen Huang, Wei Wei, Shije Xu, Siyu Chen, Jiaxin Yin, Yu Zhang, Jundong Li, Min Zheng

    The prognostic factors associated with recurrent platinum-resistant ovarian cancer treated with immune checkpoint inhibitor (ICI) therapy need to be identified. We retrospectively analyzed the efficacy of ICI therapy in patients with recurrent platinum-resistant ovarian cancer at our center. The number of CD8 + T cells and the expression of PD-L1 were assessed using immunohistochemical assays. A multi-analyte flow assay was used to detect the concentrations of 13 inflammatory cytokines. Both univariate and multivariate models were constructed using pretreatment clinical variables and cytokines. We included 71 patients with recurrent platinum-resistant ovarian cancer treated with at least two cycles of anti-programmed cell death 1 (PD-1); the objective response rate was 36.62%, and the disease control rate was 78.87%. Elevated levels of interferon-alpha 2 (IFN-α2), IL-1β, and IL-12p70 in serum were associated with improved overall survival. Higher levels of monocyte chemoattractant protein 1 (MCP-1) correlated with longer overall survival and progression free survival. According to the results of the multivariate analysis, a high level of C-reactive protein (CRP) (> 10) independently predicted overall survival. Age, low-density lipoprotein cholesterol (LDL-C), tumor necrosis factor-alpha (TNF-α), and MCP-1 were independently associated with progression-free survival. Chemotherapy containing platinum after immunotherapy progression achieved a partial response rate of 55.55%. The results of ICI combination therapy have demonstrated a response rate of over one third. Peripheral blood markers, such as cytokines, could potentially serve as predictors of immunotherapy efficacy in platinum-resistant ovarian cancer patients. Not applicable.


  • Open Access

    Super-enhancer–driven EFNA1 fuels tumor progression in cervical cancer via the FOSL2-Src/AKT/STAT3 axis

    by Shu-Qiang Liu, Xi-Xi Cheng, Shuai He, Tao Xia, Yi-Qi Li, Wan Peng, Ya-Qing Zhou, Zi-Hao Xu, Mi-Si He, Yang Liu, et al.

    Super-enhancers (SEs) are expansive cis -regulatory elements known for amplifying oncogene expression across various cancers. However, their role in cervical cancer (CC), a remarkable global malignancy affecting women, remains underexplored. Here we applied integrated epigenomic and transcriptomic profiling to delineate the distinct SE landscape in CC by analyzing paired tumor and normal tissues. Our study identifies a tumor-specific SE at the EFNA1 locus that drives EFNA1 expression in CC. Mechanically, the EFNA1-SE region contains consensus sequences for the transcription factor FOSL2, whose knockdown markedly suppressed luciferase activity and diminished H3K27ac enrichment within the SE region. Functional analyses further underlined EFNA1’s oncogenic role in CC, linking its overexpression to poor patient outcomes. EFNA1 knockdown strikingly reduced CC cell proliferation, migration, and tumor growth. Moreover, EFNA1 cis -interacted with its receptor EphA2, leading to decreased EphA2 tyrosine phosphorylation and subsequent activation of the Src/AKT/STAT3 forward signaling pathway. Inhibition of this pathway with specific inhibitors substantially attenuated the tumorigenic capacity of EFNA1-overexpressing CC cells in both in vitro and in vivo models. Collectively, our study unveils the critical role of SEs in promoting tumor progression through the FOSL2-EFNA1-EphA2-Src/AKT/STAT3 axis, providing new prognostic and therapeutic avenues for CC patients.


  • Open Access

    Surgical margin and other prognostic factors of invasive vulvar squamous cell carcinoma: A clinicopathological mono-center study

    by Binghong Guo, Jiaqi Qiu, Yulin Wang, Nuerbiya Abula, Longyi Chen, Heqing Zhao, Yongyi Zhu, Min Zheng, Zhimin Liu, Yongwen Huang


  • Open Access

    The efficacy of first and second immunotherapy exposure in patients with recurrent or metastatic cervical cancer

    by Mingxiu Ju, Baoyue Pan, Yongwen Huang, Yun Zhou, Jieping Chen, Huiling Xiang, Shije Xu, Siyu Chen, Chunyan Lan, Jundong Li, et al.

    Objective: Immunotherapy has led to changes in cervical cancer guidelines. Therefore, additional biomarkers to identify the ideal patient who would experience the most benefit may be important.Methods: We retrospectively collected 208 patients with R/M CC and recorded clinicopathologic information, peripheral blood markers and treatments to analyze the prognostic factors of clinical outcomes. Response rate comparison, univariate, and multivariate analyses were performed to assess the efficacy of different factors.Results: A total of 43.27% patients achieved objective responses, including 18 with complete response and 72 with partial response. Patients receiving first‐line immunotherapy had much higher objective response rate (ORR) than the remaining patients (53.8% vs. 34.8%, p = 0.006). CRP >3 ECOG ≥1 and recurrence in 6 months predicted shorter progression free survival (PFS). CRP >3, GLU >6.1 independently predicted unfavorable overall survival (OS). Compared with no antiangiogenic therapy, previous antiangiogenic therapy reduced the median OS by nearly 14 months. Immunotherapy rechallenge was still effective after first immunotherapy failure, and combined with dual‐immunotherapy or bevacizumab combined with chemoradiotherapy resulted in a 60.00% or 62.50% ORR, respectively. Patients with squamous cell carcinoma, with stable disease or objective response in the first immunotherapy or without chemotherapy in second immunotherapy had favorable clinical outcome.Conclusion: The baseline CRP levels in serum was an independent factor for PFS and OS of R/M CC patients treated with immunotherapy, and previous antiangiogenic therapy was associated with poor OS. Patients still show response to immunotherapy rechallenge and combined treatment with bevacizumab or candonilimab showed higher response rate than anti‐PD‐1 after immunotherapy failure.


  • Open Access

    Targeting the Cdc2‐like kinase 2 for overcoming platinum resistance in ovarian cancer

    by Yinan Jiang, Shuting Huang, Lan Zhang, Yun Zhou, Wei Zhang, Ting Wan, Haifeng Gu, Yi Ouyang, Xiaojing Zheng, Pingping Liu, et al.

    Platinum resistance represents a major barrier to the survival of patients with ovarian cancer (OC). Cdc2‐like kinase 2 (CLK2) is a major protein kinase associated with oncogenic phenotype and development in some solid tumors. However, the exact role and underlying mechanism of CLK2 in the progression of OC is currently unknown. Using microarray gene expression profiling and immunostaining on OC tissues, we found that CLK2 was upregulated in OC tissues and was associated with a short platinum‐free interval in patients. Functional assays showed that CLK2 protected OC cells from platinum‐induced apoptosis and allowed tumor xenografts to be more resistant to platinum. Mechanistically, CLK2 phosphorylated breast cancer gene 1 (BRCA1) at serine 1423 (Ser1423) to enhance DNA damage repair, resulting in platinum resistance in OC cells. Meanwhile, in OC cells treated with platinum, p38 stabilized CLK2 protein through phosphorylating at threonine 343 of CLK2. Consequently, the combination of CLK2 and poly ADP‐ribose polymerase inhibitors achieved synergistic lethal effect to overcome platinum resistance in patient‐derived xenografts, especially those with wild‐type BRCA1. These findings provide evidence for a potential strategy to overcome platinum resistance in OC patients by targeting CLK2.


  • Open Access

    The MYBL2–CCL2 axis promotes tumor progression and resistance to anti-PD-1 therapy in ovarian cancer by inducing immunosuppressive macrophages

    by Baoyue Pan, Ting Wan, Yun Zhou, Shuting Huang, Linjing Yuan, Yinan Jiang, Xiaojing Zheng, Pingping Liu, Huiling Xiang, Mingxiu Ju, et al.

    Background: An immunosuppressive tumor microenvironment in ovarian cancer facilitates tumor progression and resistance to immunotherapy. The function of MYB Proto-Oncogene Like 2 (MYBL2) in the tumor microenvironment remains largely unexplored. Methods: A syngeneic intraovarian mouse model, flow cytometry analysis, and immunohistochemistry were used to explore the biological function of MYBL2 in tumor progression and immune escape. Molecular and biochemical strategies—namely RNA-sequencing, western blotting, quantitative reverse transcription–polymerase chain reaction (qRT-PCR), enzyme-linked immunosorbent assay, multiplex immunofluorescence, chromatic immunoprecipitation assay (CHIP) and luciferase assay—were used to reveal the mechanisms of MYBL2 in the OVC microenvironment. Results: We found tumor derived MYBL2 indicated poor prognosis and selectively correlated with tumor associated macrophages (TAMs) in ovarian cancer. Mechanically, C-C motif chemokine ligand 2 (CCL2) transcriptionally activated by MYBL2 induced TAMs recruitment and M2-like polarization in vitro. Using a syngeneic intraovarian mouse model, we identified MYBL2 promoted tumor malignancyand increased tumor-infiltrating immunosuppressive macrophages. Cyclin-dependent kinase 2 (CDK2) was a known upstream kinase to phosphorylate MYBL2 and promote its transcriptional function. The upstream inhibitor of CDK2, CVT-313, reprogrammed the tumor microenvironment and reduced anti-PD-1 resistance. Conclusions: The MYBL2/CCL2 axis contributing to TAMs recruitment and M2-like polarization is crucial to immune evasion and anti-PD-1 resistance in ovarian cancer, which is a potential target to enhance the efficacy of immunotherapy.


  • Open Access

    A Nomogram for Preoperative Prediction of the Risk of Lymph Node Metastasis in Patients with Epithelial Ovarian Cancer

    by Huiling Xiang, Fan Yang, Xiaojing Zheng, Baoyue Pan, Mingxiu Ju, Shijie Xu, Min Zheng

    Objective: To develop a nomogram for predicting lymph node metastasis (LNM) in patients with epithelial ovarian cancer (EOC). Methods: Between December 2012 and August 2022, patients with EOC who received computed tomography (CT) and serological examinations and were treated with upfront staging or debulking surgery were included. Systematic pelvic and para-aortic lymphadenectomy was performed in all patients. Univariate and multivariate analysis was used to identify significant risk factors associated with LNM. A nomogram was then constructed to assess the risk of LNM, which was evaluated with respect to its area under the receiver operating characteristic curve (AUC), calibration, and clinical usefulness. Results: Of 212 patients enrolled in this study, 78 (36.8%) had positive LNs. The nomogram integrating CT-reported LN status, child-bearing status, tumour laterality, and stage showed good calibration and discrimination with an AUC of 0.775, significantly improving performance over the CT results (0.699, p = 0.0002) with a net reclassification improvement of 0.593 (p < 0.001) and integrated discrimination improvement of 0.054 (p < 0.001). The decision curve analysis showed the nomogram was of clinical use. Conclusions: A nomogram was constructed and internally validated, which may act as a decision aid in patients with EOC being considered for systemic lymphadenectomy.


  • Open Access

    Tislelizumab for cervical cancer: A retrospective study and analysis of correlative blood biomarkers

    by Xiaojing Zheng, Haifeng Gu, Xinping Cao, Baoyue Pan, Huiling Xiang, Mingxiu Ju, Shijie Xu, Min Zheng

    Background: Tislelizumab is an anti-programmed cell death 1 (PD-1) monoclonal antibody engineered to minimize binding to Fcγ receptors. It has been used to treat several solid tumors. However, its efficacy and toxicity, and the predictive and prognostic value of baseline hematological parameters in patients with recurrent or metastatic cervical cancer (R/M CC) receiving tislelizumab remain unclear.Methods: We reviewed 115 patients treated for R/M CC with tislelizumab from March 2020 to June 2022 in our institute. The antitumor activity of tislelizumab was assessed using RECIST v1.1. Associations between the baseline hematological parameters and efficacy of tislelizumab in these patients were analyzed.Results: With a median follow-up of 11.3 months (range, 2.2–28.7), the overall response rate was 39.1% (95% CI, 30.1–48.2) and the disease control rate was 77.4% (95% CI, 69.6–85.2). The median progression-free survival (PFS) was 19.6 months (95% CI, 10.7 to not reached). The median overall survival (OS) was not reached. Treatment-related adverse events (TRAEs) of any grade occurred in 81.7% of the patients and only 7.0% of the patients experienced grade 3 or 4 TRAEs. Univariate and multivariate regression analyses showed that the level of pretreatment serum C-reactive protein (CRP) was an independent risk factor for the response (complete or partial response) to tislelizumab and the PFS of R/M CC patients treated with tislelizumab (P = 0.0001 and P = 0.002, respectively). R/M CC patients with elevated baseline CRP levels had a short PFS (P = 0.0005). Additionally, the CRP-to-albumin ratio (CAR) was an independent risk factor for the PFS and OS of R/M CC patients treated with tislelizumab (P = 0.001 and P = 0.031, respectively). R/M CC patients with an elevated baseline CAR had short PFS and OS (P < 0.0001 and P = 0.0323, respectively).Conclusions: Tislelizumab showed promising antitumor activity and tolerable toxicity in patients with R/M CC. The baseline serum CRP levels and CAR showed potential for predicting the efficacy of tislelizumab and the prognosis of R/M CC patients receiving tislelizumab.